Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus
Diagnostics · 25.03.2026 · 16 (7) · 989
DOI: 10.3390/diagnostics16070989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 25.03.2026. Verfasst von Chenghao Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, Beijing 100034, China. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital's Funds for Health Improvement and Research, the Scientific and Technological Achievements Transformation Incubation Guidance Funding Project of Peking University First Hospital, the Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project.
Abstract (Originalsprache)
Background/Objectives: Traditional histopathologic grading of renal cell carcinoma (RCC) is subjective, is poorly reproducible, and fails to predict responses to modern targeted agents or immunotherapies. In the era of precision oncology, molecular pathology offers objective tools for individualized management. We aimed to characterize genomic alterations in clear-cell RCC (ccRCC) with venous tumor thrombus and to develop pathology-driven panels for personalized prognostic stratification, with exploratory assessment of their potential to predict therapeutic response.
Methods
Formalin-fixed paraffin-embedded pT1 ccRCC samples with and without thrombus underwent whole-exome sequencing. Distinct somatic mutations and copy number variations were incorporated into multigene panels. External assessment was performed in TCGA and PAWG cohorts, assessing survival outcomes and therapeutic biomarkers including homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI).
Results
Thrombus cases showed unique genomic heterogeneity compared with matched controls. Three multigene panels were constructed. Across external datasets, including a 354-patient TCGA-KIRC ccRCC cohort, the panels provided consistent molecular stratification signals for overall, disease-specific, and progression-free survival, complementing established pathological risk factors. They were significantly associated with established therapy-related genomic biomarkers, including HRD, TMB, and MSI, showing high sensitivity and negative predictive value in identifying patients unlikely to harbor these biomarker-positive profiles. These findings support the panels’ prognostic utility, with exploratory evidence for their potential in therapy response prediction.
Conclusions
Small ccRCC with thrombus harbors distinct molecular pathological features. The proposed pathology-driven panels, compatible with FFPE tissue, represent pathology-compatible genomic tools that may support modern precision pathology by improving molecular risk stratification and informing exploratory therapeutic biomarker assessment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Peking University First Hospital, Beijing 100034, China.
- Department of Biostatistics, Peking University First Hospital, Beijing 100034, China.
- Department of Urological Pathology, Peking University First Hospital, Beijing 100034, China.
ORCID-Profile: Chenghao Tan
Förderung
- Capital's Funds for Health Improvement and Research
- the Scientific and Technological Achievements Transformation Incubation Guidance Funding Project of Peking University First Hospital
- the Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project
- Capital’s Funds for Health Improvement and Research
- Scientific and Technological Achievements Transformation Incubation Guidance Funding Project of Peking University First Hospital https://ror.org/02z1vqm45
- Wuxi “Taihu Talents Program” Medical and Health High-level Talents Project
Zitieren
APA
Tan, C., He, S., Zhu, S., He, Q., He, Z., Zhou, L., & Xiong, G. (2026). Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus. Diagnostics, 16(7), 989. https://doi.org/10.3390/diagnostics16070989
Vancouver
Tan C, He S, Zhu S, He Q, He Z, Zhou L, et al. Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus. Diagnostics. 2026;16(7):989. doi:10.3390/diagnostics16070989
BibTeX
@article{Tan2026,
author = {Tan, Chenghao and He, Shiming and Zhu, Sainan and He, Qun and He, Zhisong and Zhou, Liqun and Xiong, Gengyan},
title = {Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {7},
pages = {989},
doi = {10.3390/diagnostics16070989}
}
EUVIMED